GlassScriptPhysician profile
Daniele Knight
NPI 1427570555
$1,678.06
in general payments reported to CMS, 2019-2025
18 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $721 · 2024: $256 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.66 | 2022-2025 | Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $194.39 | 2023-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $182.86 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $168.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $129.14 | 2024 | Repatha |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Genzyme Corporation | $121.64 | 2022 | |
| Impel Pharmaceuticals INC. | $99.99 | 2022 | |
| Dexcom, INC. | $73.79 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $64.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $43.41 | 2023 | |
| Inspire Medical Systems, INC. | $39.26 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $34.69 | 2022 | |
| Insulet Corporation | $23.77 | 2024 | Omnipod |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.88 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.05 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.06 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniele Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.